GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Azelaprag overview
Azelaprag (BGE-105) is under development for the treatment of muscle atrophy and obesity. It is administered through both oral and intravenous routes. The drug candidate acts by targeting apelin APJ receptor and TRPV1 receptor. It was under development for the treatment of heart failure and neuropathic pain.
BioAge Labs overview
BioAge Labs (BioAge) is a clinical-stage biotechnology company that develops a pipeline of compounds that targets the molecular causes of aging. The company uses its BioAge discovery platform, which combines the analysis of the proprietary longitudinal human samples with health records to identify the critical molecular pathways that lead to healthy human aging. Using a diverse portfolio of drugs that targets the mechanisms of aging, BioAge strives to uncover opportunities to treat or even prevent age-related diseases in innovative ways. It harnesses a pipeline portfolio of compounds, including BGE-105 (azelaprag) and BGE-100, for the treatment of muscle, immune, and brain aging. BioAge is headquartered in Richmond, California, the US.
For a complete picture of Azelaprag’s drug-specific PTSR and LoA scores, buy the report here.
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
Source link
#Azelaprag #BioAge #Labs #Muscle #Atrophy #Likelihood #Approval
